Search results for "MELLITUS"

showing 10 items of 2089 documents

Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome

2011

The metabolic syndrome (MetS) is common, and its associated risk burdens of diabetes and cardiovascular disease (CVD) are a major public health problem. The hypothesis that main constituent parameters of the MetS share common pathophysiologic mechanisms provides a conceptual framework for the future research. Exercise and weight loss can prevent insulin resistance and reduce the risk of diseases associated with the MetS. Interrupting intracellular and extracellular reactive oxygen species (ROS) overproduction could also contribute to normalizing the activation of metabolic pathways leading to the onset of diabetes, endothelial dysfunction, and cardiovascular (CV) complications. On the other…

medicine.medical_specialtyAntioxidantmedicine.medical_treatmentHyperlipidemiasDiseaseBioinformaticsmetabolic syndromeAntioxidants03 medical and health sciences0302 clinical medicineInsulin resistancecardiovascular diseaseWeight lossinsulin resistanceDiabetes mellitusInternal medicineDrug Discoverymedicineoxidative stressHumansObesityEndothelial dysfunctionantioxidants cardiovascular disease insulin resistance metabolic syndrome oxidative stress reactive oxygen species.Dyslipidemias030304 developmental biologyreactive oxygen speciesInflammationMetabolic SyndromePharmacology0303 health sciencesbusiness.industryThrombosismedicine.disease3. Good healthFatty LiverClinical trialOxidative StressantioxidantsEndocrinologyObesity Abdominal030220 oncology & carcinogenesisHypertensionInsulin ResistanceMetabolic syndromemedicine.symptombusinessSignal TransductionCurrent Pharmaceutical Design
researchProduct

Clinical and Molecular-Genetic Insights into the Role of Oxidative Stress in Diabetic Retinopathy: Antioxidant Strategies and Future Avenues

2020

Reactive oxygen species (ROS) overproduction and ROS-signaling pathways activation attack the eyes. We evaluated the oxidative stress (OS) and the effects of a daily, core nutritional supplement regimen containing antioxidants and omega 3 fatty acids (A/ω3) in type 2 diabetics (T2DM). A case-control study was carried out in 480 participants [287 T2DM patients with (+)/without (−) diabetic retinopathy (DR) and 193 healthy controls (CG)], randomly assigned to a daily pill of A/ω3. Periodic evaluation through 38 months allowed to outline patient characteristics, DR features, and classic/OS blood parameters. Statistics were performed by the SPSS 24.0 program. Diabetics displayed significantly h…

medicine.medical_specialtyAntioxidanttype 2 diabetes mellitusPhysiologyThiobarbituric acidmedicine.medical_treatmentClinical BiochemistryDietética y nutrición030209 endocrinology & metabolismmedicine.disease_causeBiochemistryArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineprevention of blindnessInternal medicineretinopathymedicineTBARSoxidative stressMolecular Biologyomega-3 fatty acidsVitamin Cbusiness.industrylcsh:RM1-950Cell BiologyDiabetic retinopathymedicine.diseaseMalondialdehydeAnatomía ocularlcsh:Therapeutics. PharmacologyantioxidantsEndocrinologychemistrycandidate biomarkers030221 ophthalmology & optometryOftalmologíabusinessOxidative stressRetinopathy
researchProduct

Arteriopatía de las extremidades inferiores y estenosis de las arterias renales

2013

Peripheral arterial disease (PAD) refers to the atherosclerotic involvement of non-coronary and extracranial arteries, including visceral arteries, the aorta and its branches and the arteries of the limbs. PAD usually refers exclusively to atherosclerosis of the limbs (in particular the lower limbs). Age, male sex, smoking and diabetes, as well as hypertension and dyslipidemia, are the most relevant risk factors for the development of PAD. PAD is frequently associated with coronary heart disease and stroke. PAD patients have increased risk of developing cardiovascular complications (coronary disease, stroke) and total and cardiovascular mortality, even after adjustment by conventional risk …

medicine.medical_specialtyAortabusiness.industrymedicine.medical_treatmentRenal functionArteriosclerosismedicine.diseaseRenal artery stenosisRevascularizationbody regionsInternal medicineDiabetes mellitusmedicine.arteryCardiologyMedicinePharmacology (medical)Cardiology and Cardiovascular MedicinebusinessStrokeDyslipidemiaClínica e Investigación en Arteriosclerosis
researchProduct

Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertas…

2021

OBJECTIVE Dyslipidemia observed in type 2 diabetes (T2D) is atherogenic. Important features of diabetic dyslipidemia are increased levels of triglyceride-rich lipoproteins and small dense LDL particles, which all have apolipoprotein B100 (apoB100) as a major apolipoprotein. This prompted us to study the effect of the GLP-1 agonist liraglutide on the metabolism of apoB100-containing lipoproteins. RESEARCH DESIGN AND METHODS We performed an in vivo kinetic study with stable isotopes (L-[1-13C]leucine) in 10 patients with T2D before and after 6 months of treatment with liraglutide (1.2 mg/day). We also evaluated in mice the effect of liraglutide on the expression of genes involved in apoB100-…

medicine.medical_specialtyApolipoprotein BEndocrinology Diabetes and MetabolismLipoproteinsAdipose tissue030209 endocrinology & metabolismLipoproteins VLDL03 medical and health sciencesMice0302 clinical medicineInternal medicineInternal MedicinemedicineAnimalsHumans030212 general & internal medicineSubtilisinsAdvanced and Specialized NursingbiologyCatabolismLiraglutidebusiness.industryPCSK9Liraglutidemedicine.diseaseLipoproteins LDLEndocrinologyDiabetes Mellitus Type 2biology.proteinKexinProprotein Convertase 9businessRetinol-Binding Proteins PlasmaDyslipidemiamedicine.drugLipoprotein
researchProduct

Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance ?

2009

Summary Background:  Statins have emerged as the global leader in pharmacologic therapy for dyslipidaemia, and rosuvastatin has demonstrated clinical efficacy as well as safety in several clinical trials and postmarketing analyses. Aim:  The present article reviewed the effects of rosuvastatin on the quantity and the quality of low-density lipoproteins (LDL). Methods:  We searched for and reviewed all the available evidence in a systematic way. A literature search (by Medline and Scopus) was performed using the following headings: ‘LDL-cholesterol’, ‘LDL size’, ‘LDL subclasses’, ‘small dense LDL’, ‘apolipoprotein B, apo B’ and ‘rosuvastatin’ up to 11 November 2008. The authors also manually…

medicine.medical_specialtyApolipoprotein BHypercholesterolemia10265 Clinic for Endocrinology and DiabetologyMEDLINE610 Medicine & health2700 General MedicinePharmacotherapyInternal medicineDiabetes mellitusmedicineHumansLDL-cholesterolRosuvastatinClinical significanceRosuvastatin CalciumAgedClinical Trials as TopicSulfonamidesbiologybusiness.industrynutritional and metabolic diseasesCholesterol LDLGeneral Medicinemedicine.diseaseFluorobenzenesPrimary PreventionClinical trialPyrimidinesTreatment OutcomeEndocrinologyCardiovascular Diseasesrosuvastatin LDL-cholesterol type-2 diabetesHMG-CoA reductasebiology.proteinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessmedicine.drug
researchProduct

Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?

2012

As the population becomes more obese and the prevalence of diabetes and the metabolic syndrome increases, low-density lipoprotein-cholesterol (LDL-C) may lose its value as a sole predictor for cardiovascular risk among lipids. Combined dyslipidemia is typically characterized by elevations in LDL-C and triglyceride levels, often accompanied by decreased high-density lipoproteincholesterol (HDL-C) concentrations and increased levels of small, dense LDL. This common disorder results from overproduction of hepatically synthesized apolipoprotein B in very low-density lipoproteins. In the last few years most of the international scientific guidelines as well as several expert panels have confirme…

medicine.medical_specialtyApolipoprotein BPopulationCombined dyslipidemia cholesterol low-density lipoprotein-cholesterol small dense low-density lipoprotein high-density lipoprotein- cholesterol non-high-density lipoprotein-cholesterolchemistry.chemical_compoundRisk FactorsInternal medicineDiabetes mellitusDrug DiscoveryAnimalsHumansMedicineeducationTriglyceridesApolipoproteins BDyslipidemiasPharmacologyLdl cholesteroleducation.field_of_studybiologyTriglyceridebusiness.industryCholesterolCholesterol HDLCholesterol LDLAtherosclerosismedicine.diseaseEndocrinologychemistryCardiovascular DiseasesPractice Guidelines as Topicbiology.proteinlipids (amino acids peptides and proteins)Metabolic syndromebusinessDyslipidemiaCurrent Pharmaceutical Design
researchProduct

Cilostazol and atherogenic dyslipidemia: a clinically relevant effect

2011

Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia.The effects of cilostazol on plasma lipids, lipoproteins, apolipoproteins and postprandial lipemia are reviewed. A literature search (using Medline and Scopus) was performed up to 24 October 2010. The authors also manually reviewed the references of selected articles for any pertinent material.Cilostazol is able to significantly lower plasma triglyceride levels, with a concomitant increase in high-density lipoprot…

medicine.medical_specialtyApolipoprotein BTetrazolescilostazol atherogenic dyslipidemiaPhosphodiesterase 3 InhibitorsPeripheral Arterial Diseasechemistry.chemical_compoundDiabetes mellitusInternal medicineHumansMedicinePharmacology (medical)DyslipidemiasPharmacologymedicine.diagnostic_testbiologybusiness.industryCholesterolGeneral MedicineAtherosclerosismedicine.diseaseLipidsCyclic Nucleotide Phosphodiesterases Type 3Intermittent claudicationCilostazolCilostazolPostprandialEndocrinologyDiabetes Mellitus Type 2chemistrybiology.proteinlipids (amino acids peptides and proteins)medicine.symptombusinessLipid profileLipoproteinmedicine.drug
researchProduct

Future perspectives of the pharmacological management of diabetic dyslipidemia

2019

Introduction: Diabetic dyslipidemia is frequent among patients with type 2 diabetes mellitus (T2DM) and is characterized by an increase in triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and small-dense (atherogenic) particles, and by a decrease in low high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A1 that are strongly related to insulin resistance. The increased flux of free fatty acids from adipose tissue to the liver aggravates hepatic insulin resistance and promotes all of aspects of the dyslipidemic state. Areas covered: Statins are the first-line agents for treatment while other lipid-lowering drugs (ezetimibe, fibrate and proprotein convertase…

medicine.medical_specialtyApolipoprotein Bmedicine.drug_classglucagon like peptide-1 receptor agonist (GLP-1RA)Fibrate030226 pharmacology & pharmacystatins03 medical and health sciences0302 clinical medicineInsulin resistanceEzetimibeInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsOmega 3 fatty acidDyslipidemiasHypolipidemic Agentsfibratebiologybusiness.industrydyslipidemianutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineLipidmedicine.diseasesodium/glucose cotransporter 2 inhibitors (SGLT-2is)LipidsEndocrinologyDiabetes Mellitus Type 2Cardiovascular Diseases030220 oncology & carcinogenesisDipeptidyl peptidase-4 inhibitors (DPP-4is)Dietary Supplementsbiology.proteinKexinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistancebusinessDyslipidemiamedicine.drugezetimibeproprotein convertase subtilisin/kexin type 9 (PCSK9)
researchProduct

Diabetes Mellitus and Its Impact on Patient-Profile and In-Hospital Outcomes in Peripheral Artery Disease

2021

Background: In patients with peripheral artery disease (PAD), the impact of diabetes mellitus (DM) on patient-profile and adverse in-hospital events is not well investigated. Methods: The German nationwide inpatient sample 2005–2019 was used for this analysis. Hospitalized PAD patients were stratified for DM and the influence of DM on patient-profile and adverse in-hospital events was investigated. Results: Our study comprised 2,654,871 hospitalizations (54.3% aged ≥70 years, 36.7% females) of patients with PAD in Germany 2005–2019. Among these, 864,691 (32.6%) patients had DM and 76,716 (2.9%) died during hospitalization. Diabetic PAD patients revealed an aggravated cardiovascular profile …

medicine.medical_specialtyArterial diseasebusiness.industrymedicine.medical_treatmentRGeneral MedicineDiseasemedicine.diseaseperipheral artery diseaseArticlemyocardial infarctionHospital outcomesAmputationInternal medicineDiabetes mellitusamputationdiabetes mellitusmedicinePatient profileMedicineMyocardial infarctionAdverse effectbusinessJournal of Clinical Medicine
researchProduct

Pilot Study on Visual Function and Fundus Autofluorescence Assessment in Diabetic Patients.

2015

Purpose. Evaluate optimized fundus autofluorescence (FAF) imaging in early stages of diabetic retinopathy (DR) and relate findings with conventional colour fundus imaging and visual function in diabetic patients and control subjects.Materials and Methods. FAF and colour images were obtained using the CR-2 Plus digital nonmydriatic retinal camera in seven diabetic patients and thirteen control subjects. Visual-Functioning Questionnaire-25 (VFQ-25) and Diabetes Self-Management Questionnaire (DSMQ) were used to assess the quality of life and diabetes self-care. Contrast sensitivity function (CSF) was evaluated with the Vistech 6500 chart.Results. FAF and optimized-FAF imaging showed more retin…

medicine.medical_specialtyArticle Subjectgenetic structuresmedia_common.quotation_subjectFundus (eye)03 medical and health scienceschemistry.chemical_compound0302 clinical medicinelcsh:OphthalmologyOphthalmologyDiabetes mellitusmedicineContrast (vision)030212 general & internal medicinemedia_commonRetinal pigment epitheliumbusiness.industryRetinalDiabetic retinopathymedicine.diseaseFundus autofluorescenceOphthalmologymedicine.anatomical_structurechemistrylcsh:RE1-994Visual function030221 ophthalmology & optometryOptometrybusinessResearch ArticleJournal of ophthalmology
researchProduct